SCHEMBL3667446

SCHEMBL3667446

C#Cc1ccc2[nH]nc(NC(=O)CN(C)C)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 10/20 0.51
CDK2 P24941 9/20 0.51
CDK1 P06493 5/20 0.51
AURKB Q96GD4 4/20 0.51
MAPK1 P28482 3/20 0.51
MAPK13 O15264 3/20 0.51
DAPK3 O43293 3/20 0.51
MAPK9 P45984 3/20 0.51
CLK2 P49760 3/20 0.51
MAPK12 P53778 3/20 0.51
CDK5 Q00535 3/20 0.51
DYRK1A Q13627 3/20 0.51
HIPK4 Q8NE63 3/20 0.51
CLK4 Q9HAZ1 3/20 0.51
PRKD3 O94806 2/20 0.51
PIM1 P11309 2/20 0.51
CDK8 P49336 2/20 0.51
MAP4K5 Q9Y4K4 2/20 0.51
DYRK3 O43781 2/20 0.51
SGK2 Q9HBY8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3670129 0.77 GSK3B (0.56) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3675188 0.76 GSK3B (0.58) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3671680 0.76 GSK3B (0.55) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3804773 0.75 GSK3B (0.55) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3670940 0.75 GSK3B (0.64) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3675235 0.75 GSK3B (0.55) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL2667995 0.75 NTRK1 (0.41) GSK3BCDK2CDK1DYRK1AGSK3A
SCHEMBL3667829 0.74 GSK3B (0.61) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3671052 0.74 GSK3B (0.54) GSK3BCDK2CDK1AURKBMAPK1
SCHEMBL3665794 0.73 GSK3B (0.58) GSK3BCDK2CDK1AURKBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885CDK2 65/4885CDK1 50/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885CDK2 65/4885CDK1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.